Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Cue Biopharma is set to report its Q2 2025 earnings on August 13th, with analysts predicting a loss of ($0.13) per share and revenue of $2.00 million.
• In its previous quarter, Cue Biopharma reported a loss of ($0.17) per share and revenues of $0.42 million, falling short of estimates.
• The stock has recently seen a 10% increase, currently trading at $0.84, with a market cap of $63.15 million.

Cue Biopharma (NASDAQ:CUE - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $2.00 million for the quarter.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). Cue Biopharma had a negative return on equity of 228.43% and a negative net margin of 507.87%. The firm had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Price Performance

Shares of NASDAQ:CUE traded up $0.03 during trading on Thursday, reaching $0.81. The stock had a trading volume of 70,393 shares, compared to its average volume of 514,388. The stock has a market capitalization of $61.03 million, a PE ratio of -1.21 and a beta of 1.53. Cue Biopharma has a 52 week low of $0.45 and a 52 week high of $1.99. The business's 50-day moving average price is $0.73 and its 200 day moving average price is $0.90.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.